Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand

Hospital-based Epidemiological Study on the Distribution of Human Papillomavirus (HPV) Types in Adult Women Diagnosed With Invasive Cervical Cancer (ICC) in New Zealand

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01328028

Enrollment

244

Registered

2011-04-04

Start date

2009-04-30

Completion date

2011-04-30

Last updated

2012-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Keywords

Invasive cervical cancer, Human papillomavirus

Brief summary

The aim of this study is to assess the distribution of the most frequent types of human papillomavirus in women diagnosed with invasive cervical cancer in New Zealand.

Interventions

OTHERTesting of archived cervical cancer tissue samples

Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.

OTHERData collection

Log sheet

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* A female aged 18 years and above at the time of cervical specimen collection, and currently residing in New Zealand. * Histological diagnoses of invasive cervical cancer stage IB or greater, within at least the last 3 years. * Written informed consent obtained from the subject/ next of kin/ Legally acceptable representative. * Availability of cervical specimen on which the diagnosis was made prior to any chemotherapy or radiotherapy. * The cervical specimen should be of appropriate size and with regular tissue specimens. * The cervical specimen should be adequately preserved. * All links to the subject's identity should be removed from the paraffin block.

Exclusion criteria

Not Applicable.

Design outcomes

Primary

Measure	Time frame
Occurrence of HPV-16 and HPV-18 in women with invasive cervical cancer	At least the last 3 years from the time of study start

Secondary

Measure	Time frame
Occurrence of other high-risk HPV types in women with invasive cervical cancer	At least the last 3 years from the time of study start
Occurrence of HPV-16/ HPV-18 co-infection with other high-risk HPV types in women with invasive cervical cancer	At least the last 3 years from the time of study start
Occurrence of low-risk HPV types in women diagnosed with invasive cervical cancer	At least the last 3 years from the time of study start

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026